What are the characteristics of DBV TECHNOLOGIES stock?

DBV TECHNOLOGIES is a company operating in the Santé · Biotechnologies · Vaccins et laboratoires de recherche sector. The stock is listed on Euronext Paris under ISIN FR0010417345.

What is the recent price evolution of DBV TECHNOLOGIES stock?

Since last close: -0.44 %. Over one week: -10.56 %. Over one year: 72.66 %.

DBV Technologies: Two Key Investor Meetings in March 2026

DBV Technologies announces its participation in two investor conferences scheduled for March. The biopharmaceutical company will present its business to investors during these events.

Published on Mar 05, 2026 at 15:24

DBV TECHNOLOGIES

2.73 € -0.44 %

Participation Details

DBV Technologies will participate in the Citizens Life Sciences Conference on March 10, 2026, in a 'Fireside Chat' format at 1:40 PM Eastern Time. The company will also be present at the Leerink Partners Global Healthcare Conference on March 11, 2026, in a one-on-one meeting format.

Live Broadcast and Recording

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

A live broadcast of the Citizens presentation will be available. A recording of the event will also be accessible in the Events section of the company's website for 90 days following the event.

🏢 Other stocks — Santé

🗞️ ABL Diagnostics Submits Takeover Bid for Texcell Amid Bankruptcy Proceedings 🗞️ Sensorion Prioritizes SENS-601 as Main Program and Discontinues SENS-501 🗞️ Sanofi Halts Phase 3 MOBILIZE Study on Riliprubart Following Unfavorable Interim Analysis 🗞️ IBA Partners with MD Anderson to Assess Clinical and Economic Value of Proton Therapy

Context

Period

Period: 1T2026

Key reported figures

Revenue: 1M€dedollars
Net income: -47,6M€dedollars
Free cash flow: -49M€dedollars

Guidance from the release

Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.

Risks mentioned

Augmentation significative des dépenses de R&D.
Perte nette en hausse à 47,6 millions de dollars.

Opportunities identified

Dépôt de la demande de licence biologique prévu pour 2026.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Participation Details

Live Broadcast and Recording

Context

Also read